Martin Gräbeldinger’s Post

View profile for Martin Gräbeldinger, graphic

Partner at BCG focusing on Biopharma R&D, MD by training, entrepreneur by mindset.

In my opinion we talk (or worry) too much about cost saving through Gen Ai, and not enough about increasing speed: Being first to market is the single biggest lever to maximise value from assets in development. https://lnkd.in/eVrKAmDE

  • table

Absolutely, the ability to accelerate time-to-market can provide a significant competitive edge and drive value creation in today's fast-paced business environment.

Like
Reply
Yanxiang Zhou

Principal at BCG | Healthcare | Biopharma | MedTech

6mo

Totally, plus longer until LoE which is the bigger lever vs. cost!

See more comments

To view or add a comment, sign in

Explore topics